Novel Biomarkers to Detect Target Organ Damage in Acute Hypertension

Hypertension and Emergency Medicine (T Rainer and P Levy, Section Editors)
  • 99 Downloads
Part of the following topical collections:
  1. Topical Collection on Hypertension and Emergency Medicine

Abstract

Purpose of Review

Early lowering of blood pressure is advised for patients with severe hypertension associated with signs of impending or progressive organ damage, whereas aggressive treatment is not recommended in patients with asymptomatic severe hypertension. As treatment goals for asymptomatic hypertension and true hypertensive emergency drastically differ, it is essential to identify patients with evidence of impending or progressive organ damage. Biomarkers may assist providers in identifying high-risk patients who would benefit from early blood pressure reduction.

Recent Findings

In this review, we discuss both currently available and investigational biomarkers that may help identify patients who might benefit from more aggressive therapy. We focus on serum and urinary biomarkers associated with acute cardiovascular, renal, and cerebrovascular damage.

Summary

There is a dearth of literature regarding the use of biomarkers to assess acute hypertension-related target organ damage. We are primarily forced to draw conclusions on the use of biomarkers from studies of related conditions such as acute heart failure. Further research is needed on the clinical significance of abnormal levels of novel biomarkers of renal, cardiac, and cerebral dysfunction in the setting of severe hypertension, particularly in those patients without overt clinical signs of organ failure.

Keywords

Hypertensive emergency Acute hypertension Hypertensive urgency Target organ damage End organ damage Biomarkers 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Chobanian AV, Bakris GL, Black HR, National High Blood Pressure Education Program Coordinating Committee, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52.  https://doi.org/10.1161/01.HYP.0000107251.49515.c2.CrossRefPubMedGoogle Scholar
  2. 2.
    Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.  https://doi.org/10.1097/01.hjh.0000431740.32696.cc.CrossRefPubMedGoogle Scholar
  3. 3.
    McNaughton CD, Self WH, Zhu Y, Janke AT, Storrow AB, Levy P. Incidence of hypertension-related emergency department visits in the United States, 2006 to 2012. Am J Cardiol. 2015;116(11):1717–23.  https://doi.org/10.1016/j.amjcard.2015.09.007.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Janke AT, CD MN, Brody AM, Welch RD, Levy PD. Trends in the incidence of hypertensive emergencies in US emergency departments from 2006 to 2013. J Am Heart Assoc. 2016 Dec 5;5(12)Google Scholar
  5. 5.
    Wolf SJ, Lo B, Shih RD, Smith MD, Fesmire FM, American College of Emergency Physicians Clinical Policies Committee. Clinical policy: critical issues in the evaluation and management of adult patients in the emergency department with asymptomatic elevated blood pressure. Ann Emerg Med. 2013;62(1):59–68.  https://doi.org/10.1016/j.annemergmed.2013.05.012.CrossRefPubMedGoogle Scholar
  6. 6.
    •• Levy PD, Mahn JJ, Miller J, et al. Blood pressure treatment and outcomes in hypertensive patients without acute target organ damage: a retrospective cohort. Am J Emerg Med. 2015;33(9):1219–24. This paper demonstrated that, regardless of the degree of blood pressure elevation, patients presenting to the emergency department with severe hypertension without organ damage did not derive benefit from early initiation of antihypertensive therapy. CrossRefPubMedGoogle Scholar
  7. 7.
    Mahajan N, Mehta Y, Rose M, et al. Elevated troponin level is not synonymous with myocardial infarction. Int J Cardiol. 2006;111:442–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Taniguchi R, Sato Y, Nishio Y, et al. Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies. Heart Vessel. 2006;21:344–9.CrossRefGoogle Scholar
  9. 9.
    Ammann P, Maggiorini M, Bertel O, Haenseler E, Joller-Jemelka HI, Oechslin E, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol. 2003;41(11):2004–9.  https://doi.org/10.1016/S0735-1097(03)00421-2.CrossRefPubMedGoogle Scholar
  10. 10.
    Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116(4):427–33.  https://doi.org/10.1161/CIRCULATIONAHA.106.680421.CrossRefPubMedGoogle Scholar
  11. 11.
    Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106(23):2941–5.  https://doi.org/10.1161/01.CIR.0000041254.30637.34.CrossRefPubMedGoogle Scholar
  12. 12.
    Su Y-C, Huang K-F, Yang F-Y, Lin S-K. Elevation of troponin I in acute ischemic stroke. PeerJ. 2016;4:e1866.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kertai MD, Boersma E, Klein J, et al. Long-term prognostic value of asymptomatic cardiac troponin T elevations in patients after major vascular surgery. Eur J Vasc Endovasc Surg. 2004;28:59–66.CrossRefPubMedGoogle Scholar
  14. 14.
    Pattanshetty DJ, Bhat PK, Aneja A, Pillai DP. Elevated troponin predicts long-term adverse cardiovascular outcomes in hypertensive crisis: a retrospective study. J Hypertens. 2012;30(12):2410–5.  https://doi.org/10.1097/HJH.0b013e3283599b4f.CrossRefPubMedGoogle Scholar
  15. 15.
    • Afonso L, Bandaru H, Rathod A, Badheka A, Kizilbash A, et al. Prevalence, determinants, and clinical significance of cardiac troponin-I elevation in individuals admitted for a hypertensive emergency. J Clin Hypertens. 2011;13:551–6. This study is notable for both highlighting a very high mortality rate among patients with hypertensive emergency and also for demonstrating that elevated troponin levels in acute hypertension, absent acute coronary syndrome, may not be independently associated with increased mortality. CrossRefGoogle Scholar
  16. 16.
    Maludum O, Shah M, Mezue K, Biso S, Rodriguez-Ziccardi M, et al. Factors that influence decision for ischemic work-up in hypertensive emergency. Int J Cardiol. 2016 Jul 1;214:331–2.CrossRefPubMedGoogle Scholar
  17. 17.
    Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation. 2007;116(3):249–57.  https://doi.org/10.1161/CIRCULATIONAHA.107.694562.CrossRefPubMedGoogle Scholar
  18. 18.
    Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011;13(7):718.CrossRefPubMedGoogle Scholar
  19. 19.
    Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin and outcomes in acute heart failure. N Engl J Med. 2008;258:2117–26.CrossRefGoogle Scholar
  20. 20.
    Niederkofler EE, Kierna UA, O’Rear J, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2008;1(4):258–64.  https://doi.org/10.1161/CIRCHEARTFAILURE.108.790774.CrossRefPubMedGoogle Scholar
  21. 21.
    Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350(mar04 22):h910.  https://doi.org/10.1136/bmj.h910.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M, ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49(19):1943–50.  https://doi.org/10.1016/j.jacc.2007.02.037.CrossRefPubMedGoogle Scholar
  23. 23.
    •• Peacock F, Amin A, Granger CB, Pollack CV, Levy P, et al. Hypertensive heart failure: patient characteristics, treatment, and outcomes. Am J Emerg Med. 2011;(8):855–62. This retrospective study of over 12,000 patients is perhaps the largest and best study on the prognostic significance of abnormal biomarkers (natriuretic peptides) in patients with hypertensive emergency. Google Scholar
  24. 24.
    Kato J, Tsuruda T, Kita T, Kitamura K, Eto T. Adrenomedullin: a protective factor for blood vessels. Arteriorscler Thromb Vasc Biol. 2005;25:2480–7.CrossRefGoogle Scholar
  25. 25.
    Funke-Kaiser A, Mann K, Colquhoun D, et al. Mid- regional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. Int J Cardiol. 2014;172:411–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Suberviola B, Castellanos-Ortega A, Llorca J, Ortiz F, Iglesias D, Prieto B. Prognostic value of proad- renomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. Swiss Med Wkly. 2012;142:w13542.PubMedGoogle Scholar
  27. 27.
    Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck J, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest. 2009;136(3):823–31.  https://doi.org/10.1378/chest.08-1981.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    • Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in ACute Heart failure) trial. J Am Coll Cardiol. 2010;55:2062–76. The BACH trial highlighted the potential prognostic implications of both MR-ProADM and Copeptin in the acute care setting. CrossRefPubMedGoogle Scholar
  29. 29.
    Shah KS, Marston NA, Mueller C, Neath SX, Christenson RH, McCord J, et al. Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial. Acad Emerg Med. 2015;22(5):554–63.  https://doi.org/10.1111/acem.12649.CrossRefPubMedGoogle Scholar
  30. 30.
    Maisel A, Xue Y, Shah K, Mueller C, Nowak R, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin; secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail. 2011;4:613–20.CrossRefPubMedGoogle Scholar
  31. 31.
    Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med. 2012;10(1):7.  https://doi.org/10.1186/1741-7015-10-7.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Maisel A, Mueller C, Neath SX, Christenson RH, Morgenthaler NG. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). J Am Coll Cardiol. 2013;62(2):150–60.CrossRefPubMedGoogle Scholar
  33. 33.
    Wildi K, Zellweger C, Twerenbold R, Jaeger C, Reichlin T. Incremental value of copeptin to highly sensitive cardiac troponin I for rapid rule-out of myocardial infarction. Int J Cardiol. 2015;190(1):170–6.  https://doi.org/10.1016/j.ijcard.2015.04.133.CrossRefPubMedGoogle Scholar
  34. 34.
    Villacorta H, Maisel AS. Soluble ST2 testing: a promising biomarker in the management of heart failure. Arq Bras Cardiol. 2016;106(2):145–52.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Gaggin HK, Januzzi JL. Cardiac biomarkers and heart failure. http://www.acc.org/latest-in-cardiology/articles/2015/02/09/13/00/cardiac-biomarkers-and-heart-failure. Published Feb 10, 2015. Accessed 29 June 2017.
  36. 36.
    Parikh R, Seliger S, Christenson R, et al. Soluble ST2 for prediction of heart failure and cardiovascular death in an elderly, community-dwelling population. J Am Heart Assoc. 2016;5:3003188.CrossRefGoogle Scholar
  37. 37.
    Januzzi J, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50(7):607–13.  https://doi.org/10.1016/j.jacc.2007.05.014.CrossRefPubMedGoogle Scholar
  38. 38.
    • Derhaschnig U, Testori C, Riedmueller E, et al. Decreased renal function in hypertensive emergencies. J Hum Hypertens. 2014;28(7):427–31. This is one of only a few studies to specifically address the use of urinary biomarkers (NGAL) in the setting of hypertensive emergency in the emergency department. CrossRefPubMedGoogle Scholar
  39. 39.
    Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73(9):1008–16.  https://doi.org/10.1038/sj.ki.5002729.CrossRefPubMedGoogle Scholar
  40. 40.
    Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens. 2015;24(3):295–300.  https://doi.org/10.1097/MNH.0000000000000115.CrossRefPubMedGoogle Scholar
  41. 41.
    Garcia-Carretero R, Vigil-Medina L, Barquero-Perez O, Goya-Esteban R, Mora-Jimenez, et al. Cystatin C as a predictor of cardiovascular outcomes in a hypertensive population. J Hum Hyperten. 2017;31(12):801–7.  https://doi.org/10.1038/jhh.2017.68.CrossRefGoogle Scholar
  42. 42.
    Soto K, Coelho S, Rodrigues B, Martin H, Frade F, et al. Cystatin C as a marker of acute kidney injury in the emergency department. Clin J Am Soc Nephrol. 2010 Oct;5(10):1745–54.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Zhang Z, Lu B, Sheng X, Jin N. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Am J Kidney Dis. 2011 Sep;58(3):356–65.  https://doi.org/10.1053/j.ajkd.2011.02.389.CrossRefPubMedGoogle Scholar
  44. 44.
    Murty MSN, Sharma UK, Pandey VB, Kankare SB. Serum cystatin C as a marker of renal function in detection of early acute kidney injury. Indian J Nephrol. 2013;23(3):180–3.  https://doi.org/10.4103/0971-4065.111840.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Bolignano D, Donato V, Coppolino G, Campo SC, Buemi A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008 Sep;52(3):595–605.  https://doi.org/10.1053/j.ajkd.2008.01.020.CrossRefPubMedGoogle Scholar
  46. 46.
    • Nickolas TL, O'Rourke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008;148:810–9. The results of this study suggest that NGAL is highly predictive of developing acute kidney injury and also shows promise in discriminating acute kidney injury from chronic/non-progressive renal disease. CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Corbacioglu SK, Cevik Y, Akinci E, Uzunosmanoglu H, Dagar S, et al. Value of plasma neutrophil gelatinase-associated lipocalin (NGAL) in distinguishing between acute kidney injury (AKI) and chronic kidney disease (CKD). Turk J Emerg Med. 2017;17(3):85–8.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Palazzuoli A, Ruocco G, Pellegrini M, De Gori C, Del Castillo G, et al. Comparison of neutrophil gelatinase-associated lipocalin versus B-type natriuretic peptide and cystatin C to predict early acute kidney injury and outcome in patients with acute heart failure. Am J Cardiol. 2015 Jul 1;116(1):104–11.CrossRefPubMedGoogle Scholar
  49. 49.
    Mårtensson J, Bellomo R. The rise and fall of NGAL in acute kidney injury. Blood Purif. 2014;37(4):304–10.  https://doi.org/10.1159/000364937.CrossRefPubMedGoogle Scholar
  50. 50.
    Haase M, Mertens PR. Biomarkers: more than just markers! Nephrol Dial Transplant. 2015 Jan;30(1):33–8.  https://doi.org/10.1093/ndt/gfu085.CrossRefPubMedGoogle Scholar
  51. 51.
    Huang Y, Don-Wauchope AC. The clinical utility of kidney injury molecule 1 in the prediction, diagnosis and prognosis of acute kidney injury: a systematic review. Inflamm Allergy Drug Targets. 2011;10(4):260–71.  https://doi.org/10.2174/187152811796117735.CrossRefPubMedGoogle Scholar
  52. 52.
    Shao X, Tian L, Xu W, Zhang Z, Wang C, Qi C, et al. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One. 2014;9(1):e84131.  https://doi.org/10.1371/journal.pone.0084131.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Kadioglu T, Uzunlulu M, Yigit Kaya S, Oguz A, Gonenli G, Isbilen B, et al. Urinary kidney injury molecule-1 levels as a marker of early kidney injury in hypertensive patients. Minerva Urol Nefrol. 2016;68(5):456–61.PubMedGoogle Scholar
  54. 54.
    Bustamante A, Lopez-Cancio E, Pich S, Panalba A, Giralt D, et al. Blood biomarkers for the early diagnosis of stroke: the Stroke-Chip study. Stroke. 2017;48(9):2419–25.CrossRefPubMedGoogle Scholar
  55. 55.
    Karabacak M, Yigit M, Turkdogan KA, Yigit E, Selek S. Is signal peptide-CUB-EGF domain-containing protein1 a diagnostic biomarker in patients with hypertensive crises. Clin Hemorheol Microcirc. 2015;61(3):513–22.  https://doi.org/10.3233/CH-141917.CrossRefPubMedGoogle Scholar
  56. 56.
    Haapaniemi E, Tatlisumak T. Is D-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurol Scand. 2009;119(3):141–50.  https://doi.org/10.1111/j.1600-0404.2008.01081.x.CrossRefPubMedGoogle Scholar
  57. 57.
    Xu Q, Tian Y, Peng H, Li H. Copeptin as a biomarker for prediction of prognosis of acute ischemic stroke and transient ischemic attack: a meta-analysis. Hypertens Res. 2017;40(5):465–71.  https://doi.org/10.1038/hr.2016.165.CrossRefPubMedGoogle Scholar
  58. 58.
    Blum CA, Winzeler B, Nigro N, Schuetz P, Biethahn S, et al. Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study. J Headache Pain. 2017;18(1):21.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Bannay A, Husain A, Bohm M, Wagenpfeil S. Outcomes after hypertensive crisis: comparison between diabetics and nondiabetics. IJC Metab Endocr. 2015;7:25–30.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Departments of Emergency Medicine and Internal MedicineBaylor College of MedicineHoustonUSA
  2. 2.Department of Emergency MedicineBaylor College of MedicineHoustonUSA

Personalised recommendations